News | Hemodynamic Support Devices | September 20, 2018

Abiomed Showcases Expanded FDA Indications, Next-Generation Heart Recovery Products at TCT 2018

Company will feature cath lab experience and demonstrations, presentations on Protected PCI and cardiogenic shock

Abiomed Showcases Expanded FDA Indications, Next-Generation Heart Recovery Products at TCT 2018

September 19, 2018 — Abiomed Inc. announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference will highlight the recently expanded U.S. Food and Drug Administration (FDA) indications for high-risk percutaneous coronary intervention (PCI) and cardiogenic shock. Initiatives will also highlight Protected PCI’s ability to allow for more complete revascularization, which improves outcomes1 and quality of life2,3. More than 30 presentations as well as live cases featuring Impella heart pumps are expected at TCT 2018, taking place Sept. 21-25 in San Diego, California.

New for TCT 2018, Abiomed’s booth will feature a cath lab experience with demonstrations and simulations of advancements including:

  • Abiomed’s augmented reality simulator which provides hands-on experience with the Impella RP and the newly FDA approved Impella CP with SmartAssist, which includes hemodynamic sensors to intelligently position and manage the device;
  • Simulations of Impella CP with SmartAssist’s real-time informational displays of new hemodynamic metrics; and
  • Live demonstrations of Abiomed’s latest innovation, Impella Connect, which provides real-time information in the cloud to connect remote support resources.

In the hemodynamic support and patient management pavilion, Abiomed is hosting practical, hands-on workshops on large bore access and closure, advanced hemodynamics, best practices in cardiogenic shock and complex Protected PCI strategies.

Watch the VIDEO Cardiogenic Shock Supported With Impella Shows Good Outcomes

A breakfast symposium on Saturday, Sept. 22 at 6:30 a.m. will feature data on Abiomed’s FDA approval for cardiogenic shock associated with cardiomyopathy, including peripartum and postpartum cardiomyopathy. Faculty will also discuss the role of ventricular unloading and the latest results from the National Cardiogenic Shock Initiative (NCSI). Initial NCSI data showed 76 percent survival and 100 percent native heart recovery when the NCSI protocol and best practices were used.

Watch the VIDEO Overview of the National Cardiogenic Shock Initiative

Protected PCI with Impella allows for more complete revascularization, which improves outcomes and quality of life. Abiomed anticipates the broadcast of several elective high-risk PCI live cases using hemodynamic support with the Impella heart pump.

The schedule for Protected PCI and cardiogenic shock related TCT symposia is included below.

Saturday, Sept. 22

Co-sponsored Symposium:New Treatment Strategies for Cardiogenic Shock: Impella Expanded Indications

6:30–8:00 a.m. | Room 23 B-C

  • Cindy Grines, M.D.: Advances in the Treatment of Cardiovascular Disease in Women: PCI, MI, Shock, Myocarditis, SCAD and Post-partum Cardiomyopathy
  • William O’Neill, M.D.: The Impact of The Cardiogenic Shock Initiative (NCSI): One Year Later
  • Navin Kapur, M.D.: Understanding the Importance of Ventricular Unloading in Management of AMI and Cardiogenic Shock

 

Presentation Theater Program: Contrast-Induced Acute Kidney Injury – Preventive Measures That Work

Saturday, Sept. 22 | 11:30 a.m.–12:30 p.m.

San Diego Convention Center, Presentation Theater 2, Hall B2, Ground Level

CHIP Angiogram Review: What’s New with Focused Case Presentations

Saturday, Sept. 22 | 6:30–8:00 p.m.

Marriott Marquis San Diego Marina, Pacific Ballroom 18-19

Sunday, Sept. 23

Co-sponsored Symposium: Management of Complex PCI Patients: Award-winning Case Presentations

6:30–8:00 a.m. | Room 23 B-C

Chair: David Wohns, M.D.

Faculty: Amir Kaki, M.D.; George Vetrovec, M.D.

Interactive Training Pavilion: Hemodynamic Support & Patient Management

Saturday, Sept. 22 and Sunday, Sept. 23

  • Large Bore Access & Closure
    • Faculty: Amir Kaki, M.D.; James McCabe, M.D.; Raj Tayal, M.D.
  • Cardiogenic Shock (NCSI)
    • Faculty: Navin Kapur, M.D.; William O’Neill, M.D.; Brian Porvin, M.D.
  • TEACH Intro
    • Faculty: Dan Burkoff, M.D.; Reshad Garan, M.D.; John Lasala, M.D.; Salvatore Mannino, M.D.; Perwaiz Meraj, M.D.; Lynn Morris, M.D.; Raj Patel, M.D.; Brian Porvin, M.D.
  • Complex Protected PCI
    • Faculty: Hiram Bezerra, M.D.; Dan Burkoff, M.D.; Mauricio Cohen, M.D.; Colin Hirst, M.D.; Paul Mahoney, M.D.; Duane Pinto, M.D.; Uma Rangasetty, M.D.; Adhir Shroff, M.D.

For more information: www.abiomed.com

Related Content

VIDEO: Hemodynamic Support Protocols at Henry Ford Hospital

References

  1. Dangas, G. et al. Am. Journ of Cardiol. 2014 Jan 15;113(2):222-8.
  2. Abiomed data on file.
  3. O'Neill, W. et al. Circulation. 2012 Oct 2;126(14):1717-27.

Related Content

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials prese
TCT 2020 Late-breaking Study trial Presentations Announced. #TCTconnect #TCT2020 #TCT
Feature | TCT | October 29, 2020
October 29, 2020 — The late-breaking studies are one of the hallmarks of the annual...
Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

News | TCT | October 14, 2020
October 14, 2020 — The American College of Cardiology (ACC) and the...
Videos | TCT | August 01, 2020
With COVID-19 forcing all medical conferences to go virtual in 2020,...
EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment for structural heart procedures. #TCT2019 #TCT #TCT19

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment in structural heart procedures. (Photos by Dave Fornell)

Feature | TCT | November 04, 2019 | Dave Fornell, Editor
The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...
TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019
The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late-breaking science...
Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the ex
cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.
Feature | TCT | September 21, 2018
October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clini
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics. #TCT #TCT18 #TCT2018
Feature | TCT | September 14, 2018 | Dave Fornell, Editor
The volume of information attendees receive at the annual...